Rigel Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Rigel Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Profit Cash Ratio: Over the last 3 years, every $100 of reported profit came with $28 of operating cash. Lower than 95% of Healthcare companies in United States.
- Growth Efficiency Ratio: Sales grew 145% in 3 years; of every extra $100 of sales, $245 became extra profit. Higher than 88% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 2 of the last 3 years; profit grew in 3 of 3. Steadier than 85% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
$28Over the last 3 years, every $100 of reported profit came with $28 of operating cash.
Lower than 95% of Healthcare companies in United States.
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
$19For every $100 of sales, $19 is tied up in day-to-day operations (money owed by customers + stock − money owed to suppliers), against $22 tied up three years earlier.
Less money tied up than 60% of Healthcare companies in United States.
Growth quality
Steadiness Ratio
2/3 · 3/3Sales grew in 2 of the last 3 years; profit grew in 3 of 3.
Steadier than 85% of Healthcare companies in United States.
Growth Efficiency Ratio
$245Sales grew 145% in 3 years; of every extra $100 of sales, $245 became extra profit.
Higher than 88% of Healthcare companies in United States.
Asset Productivity Ratio
+145% / +282%In 3 years sales changed by +145% while total assets changed by +282%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
2.5×Debt due within a year is covered 2.5 times by its yearly operating cash.
Higher than 75% of Healthcare companies in United States.
Cash Cushion Ratio
+11%Cash, after subtracting all debt, equals 11% of its market value (net cash).
Higher than 52% of Healthcare companies in United States.
Tangible Assets Ratio
95%Of every $100 the company owns, $95 is in tangible assets such as plants, cash, stock and receivables; the rest is goodwill and other intangibles.
More tangible than 73% of Healthcare companies in United States.
Tangible Net Worth Ratio
94%Of every $100 of net worth, $94 is tangible; the rest is goodwill and other intangibles, often from buying other companies.
More tangible than 78% of Healthcare companies in United States.
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
Rigel Pharmaceuticals, Inc. owes $0.18 for every $1 it owns. Net profit rose 1999% in the year to Dec 2025.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
2.9Investors pay $2.9 for every $1 of Rigel Pharmaceuticals, Inc.'s yearly profit, lower than 88% of Healthcare companies in United States.
P/B ratio
2.11The share price is 2.11 times Rigel Pharmaceuticals, Inc.'s book value per share, lower than 56% of Healthcare companies in United States.
Market cap
$899 MThe total market value of all of Rigel Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), larger than 62% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$425 MWhat Rigel Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$22.77Net worth divided by the number of shares. The share price of $48.13 is 2.1 times this, which is the P/B above.
Return on equity (ROE)
126.9%Rigel Pharmaceuticals, Inc. earned 126.9% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
Owes vs Owns
0.18×Rigel Pharmaceuticals, Inc. owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Dividend yield
NoneRigel Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
+64%Revenue rose 64% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Profit growth
+1999%Net profit rose 1999% in the year to Dec 2025.
Profit margin
124.7%Rigel Pharmaceuticals, Inc. keeps $125 of every $100 of revenue as net profit.
Cash quality
0.2×Cash from Rigel Pharmaceuticals, Inc.'s business was 0.2× its reported profit in the year to Dec 2025 — less cash came in than the profit reported.
Interest cover
17.1×Rigel Pharmaceuticals, Inc.'s operating profit covered its interest costs 17.1 times in the year to Dec 2025.
Cash vs debt
Net cashRigel Pharmaceuticals, Inc. held $102 M more cash than debt (net cash) at Dec 2025.
Questions
What is Rigel Pharmaceuticals, Inc.'s P/E ratio?
Investors pay $2.9 for every $1 of Rigel Pharmaceuticals, Inc.'s yearly profit, lower than 88% of Healthcare companies in United States.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Rigel Pharmaceuticals, Inc.: $899 M ÷ $425 M (30 Jun 2026) = 2.1.
What is Rigel Pharmaceuticals, Inc.'s return on equity?
Rigel Pharmaceuticals, Inc. earned 126.9% on its shareholders' money over the last year, higher than almost all Healthcare companies in United States.
How much does Rigel Pharmaceuticals, Inc. owe compared with what it owns?
Rigel Pharmaceuticals, Inc. owes $0.18 for every $1 it owns (low), lower than 75% of Healthcare companies in United States.
Does Rigel Pharmaceuticals, Inc. pay a dividend?
No. Rigel Pharmaceuticals, Inc. does not currently pay a dividend.
Is Rigel Pharmaceuticals, Inc.'s revenue growing?
Revenue rose 64% in the year to Dec 2025, and grew 35% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.